blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1954709

EP1954709 - E2EPF UBIQUITIN CARRIER PROTEIN-VON HIPPEL-LINDAU INTERACTION AND USES OF THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.02.2016
Database last updated on 15.06.2024
Most recent event   Tooltip13.10.2017Lapse of the patent in a contracting state
New state(s): BG, CY, HU, SE, TR		published on 15.11.2017  [2017/46]
Applicant(s)For all designated states
Korea Research Institute of Bioscience and Biotechnology
111 Gwahangno
Yuseong-gu
Daejeon 305-806 / KR
[N/P]
Former [2008/33]For all designated states
Korea Research Institute of Bioscience and Biotechnology
111 Gwahangno Yuseong-gu
Daejeon 305-806 / KR
Inventor(s)01 / IM, Dong-Soo
No:107-604 Hanwool Apt. Sinsung-dong Yuseong-gu
Daejeon 305-345 / KR
02 / JUNG, Cho-Rok
504 City Villa, Bongmyong-dong 640-70, Yuseong-gu
Daejeon 305-301 / KR
03 / HWANG, Kyung-Sun
106-6, Jayang-dong
Dong-gu
Daejeon 308-830 / KR
04 / JUNG HWA, Lim
125 Gwahak-ro, Yuseong-gu
Daejeon 305-806 / KR
 [2015/12]
Former [2008/43]01 / IM, Dong-Soo
No:107-604 Hanwool Apt. Sinsung-dong Yuseong-gu
Daejeon 305-345 / KR
02 / JUNG, Cho-Rok
504 City Villa, Bongmyong-dong 640-70, Yuseong-gu
Daejeon 305-301 / KR
03 / HWANG, Kyung-Sun
106-6, Jayang-dong Dong-gu
Daejeon 308-830 / KR
Former [2008/41]01 / IM, Dong-Soo
No:107-604 Hanwool Apt. Sinsung-dong Yuseong-gu
Daejeon 305-345 / KR
02 / JUNG, Cho-Rok
504 City Villa, Bongmyong-dong 640-70, Yuseong-gu
Daejeon 305-301 / KR
03 / HWANG, Kyung-Sun
No:108-501 Sangroksu Apt. 281 Manyeon-dong Seo-gu
Daejeon 302-150 / KR
Former [2008/33]01 / IM, Dong-Soo
No:107-604 Hanwool Apt. Sinsung-dong Yuseong-gu
Daejeon 305-345 / KR
02 / JUNG, Cho-Rok
No:303 Jangbangapartvilla 118-27 Sinsung-dong Yuseong-gu
Daejeon 305-345 / KR
03 / HWANG, Kyung-Sun
No:108-501 Sangroksu Apt. 281 Manyeon-dong Seo-gu
Daejeon 302-150 / KR
Representative(s)Office Freylinger
P.O. Box 48
8001 Strassen / LU
[2015/16]
Former [2009/27]Office Freylinger
P.O. Box 48
8001 Strassen / LU
Former [2008/33]Kihn, Pierre Emile Joseph, et al
Office Ernest T. Freylinger S.A. 234, route d'Arlon B.P. 48
8001 Strassen / LU
Application number, filing date06812582.213.11.2006
[2008/33]
WO2006KR04749
Priority number, dateKR2005010801411.11.2005         Original published format: KR 20050108014
[2008/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2007055547
Date:18.05.2007
Language:EN
[2007/20]
Type: A1 Application with search report 
No.:EP1954709
Date:13.08.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 18.05.2007 takes the place of the publication of the European patent application.
[2008/33]
Type: B1 Patent specification 
No.:EP1954709
Date:15.04.2015
Language:EN
[2015/16]
Search report(s)International search report - published on:KR18.05.2007
(Supplementary) European search report - dispatched on:EP26.10.2010
ClassificationIPC:C07K14/47, C12N9/00, C12N15/113
[2014/18]
CPC:
C12N9/93 (EP,US); C07K1/00 (KR); A61P35/00 (EP);
A61P43/00 (EP); A61P9/10 (EP); C07K1/06 (KR);
C07K14/4703 (EP,US); C07K14/4738 (EP,US); C12N15/1137 (EP,US);
C12N15/86 (KR); C12N15/867 (KR); C12Y603/02019 (EP,US);
C12N2310/111 (EP,US); C12N2310/14 (EP,US) (-)
Former IPC [2008/33]C07K1/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/16]
Former [2008/33]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:VON-HIPPEL-LINDAU-WECHSELWIRKUNG ZWISCHEN E2EPF UND DEM UBIQUITIN-TRÄGERPROTEIN UND ANWENDUNGEN DAVON[2008/33]
English:E2EPF UBIQUITIN CARRIER PROTEIN-VON HIPPEL-LINDAU INTERACTION AND USES OF THEREOF[2008/33]
French:INTERACTION PROTEINE PORTEUSE D'UBIQUITINE (UCP) E2EPF-VON HIPPEL-LINDAU, ET SES UTILISATIONS[2008/33]
Entry into regional phase04.06.2008National basic fee paid 
04.06.2008Search fee paid 
04.06.2008Designation fee(s) paid 
04.06.2008Examination fee paid 
Examination procedure04.06.2008Examination requested  [2008/33]
03.05.2011Amendment by applicant (claims and/or description)
15.10.2012Despatch of a communication from the examining division (Time limit: M04)
22.02.2013Reply to a communication from the examining division
30.10.2014Communication of intention to grant the patent
09.03.2015Fee for grant paid
09.03.2015Fee for publishing/printing paid
09.03.2015Receipt of the translation of the claim(s)
Divisional application(s)EP15158221.0  / EP3018202
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.10.2012
Opposition(s)18.01.2016No opposition filed within time limit [2016/12]
Fees paidRenewal fee
19.11.2008Renewal fee patent year 03
13.10.2009Renewal fee patent year 04
14.10.2010Renewal fee patent year 05
14.10.2011Renewal fee patent year 06
15.10.2012Renewal fee patent year 07
13.09.2013Renewal fee patent year 08
28.11.2014Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.11.2006
AT15.04.2015
BE15.04.2015
BG15.04.2015
CY15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
MC15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SE15.04.2015
SI15.04.2015
SK15.04.2015
TR15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
IE13.11.2015
LU13.11.2015
CH30.11.2015
FR30.11.2015
LI30.11.2015
[2017/39]
Former [2016/50]AT15.04.2015
BE15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
MC15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SI15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
IE13.11.2015
LU13.11.2015
CH30.11.2015
FR30.11.2015
LI30.11.2015
Former [2016/45]AT15.04.2015
BE15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
MC15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SI15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
IE13.11.2015
LU13.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/37]AT15.04.2015
BE15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
MC15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SI15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
LU13.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/34]AT15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
MC15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SI15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
LU13.11.2015
CH30.11.2015
LI30.11.2015
Former [2016/31]AT15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
MC15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SI15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
LU13.11.2015
Former [2016/28]AT15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
MC15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SI15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2016/24]AT15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SI15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2016/21]AT15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
IT15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2016/10]AT15.04.2015
CZ15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
PL15.04.2015
RO15.04.2015
SK15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2016/09]AT15.04.2015
DK15.04.2015
EE15.04.2015
ES15.04.2015
FI15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2016/07]AT15.04.2015
DK15.04.2015
ES15.04.2015
FI15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2015/51]AT15.04.2015
ES15.04.2015
FI15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2015/50]ES15.04.2015
FI15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
GR16.07.2015
IS15.08.2015
PT17.08.2015
Former [2015/49]ES15.04.2015
FI15.04.2015
LT15.04.2015
LV15.04.2015
NL15.04.2015
GR16.07.2015
PT17.08.2015
Former [2015/42]NL15.04.2015
Documents cited:Search[XI]US2003232436  (MONIA BRETT P [US], et al) [X] 1,2,7,8,14,15 * page 8, paragraph 59 - paragraph 60; claims 1,2; table 1 * [I] 6,11;
 [X]US2005037389  (SANTIN ALESSANDRO D [US]) [X] 7,8,14,15 * claims 5-7 *;
 [XP]WO2006044366  (NOVARTIS AG [CH], et al) [XP] 1-3,7,8 * page 11, paragraph 3; claims 1-6, 18 * * page 12, paragraph 1 *;
 [X]  - WAGNER K W ET AL, "Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin", ONCOGENE, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1038/SJ.ONC.1207861, (20040826), vol. 23, no. 39, ISSN 0950-9232, pages 6621 - 6629, XP002387890 [X] 1,2 * abstract *

DOI:   http://dx.doi.org/10.1038/sj.onc.1207861
 [X]  - OHH M ET AL, "Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein", NATURE CELL BIOLOGY, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1038/35017054, (20000701), vol. 2, no. 7, ISSN 1465-7392, pages 423 - 427, XP002388870 [X] 9,12,13 * abstract *

DOI:   http://dx.doi.org/10.1038/35017054
 [XP]  - JUNG CHO-ROK ET AL, "E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis", NATURE MEDICINE, (200607), vol. 12, no. 7, ISSN 1078-8956, pages 809 - 816, XP002603020 [XP] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/NM1440
 [X]  - KAMURA T ET AL, "A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M203344200, (20020816), vol. 277, no. 33, ISSN 0021-9258, pages 30388 - 30393, XP002998911 [X] 9,10 * abstract *

DOI:   http://dx.doi.org/10.1074/jbc.M203344200
International search[Y]US2003003564  (TYERS MIKE [CA], et al);
 [A]US6858709  (CONAWAY JOAN W [US], et al);
 [A]US6737244  (ISSAKANI SARKIZ D [US], et al)
 [Y]  - NA X. ET AL., J. UROL., (200308), vol. 170, no. 2, PART 1, pages 588 - 592, XP005536144

DOI:   http://dx.doi.org/10.1097/01.ju.0000074870.54671.98
 [A]  - MAYNARD M.A. ET AL., CURR. CANCER DRUG TARGETS, (200508), vol. 5, no. 5, pages 345 - 356, XP008126417

DOI:   http://dx.doi.org/10.2174/1568009054629672
 [A]  - LI Z. ET AL., EMBO REPORTS, (20050318), vol. 6, no. 4, pages 373 - 378, XP003012836

DOI:   http://dx.doi.org/10.1038/sj.embor.7400377
 [A]  - KAMURA T. ET AL., JBC, (2002), vol. 277, no. 33, pages 30388 - 30393, XP002998911

DOI:   http://dx.doi.org/10.1074/jbc.M203344200
Examination   - BUNONE ET. AL., "Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features", AMERICAN JOURNAL OF PATHOLOGY, (19991206), vol. 155, no. 6, pages 1967 - 1976
    - BUNONE G ET AL, "Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.", THE AMERICAN JOURNAL OF PATHOLOGY DEC 1999 LNKD- PUBMED:10595926, (199912), vol. 155, no. 6, ISSN 0002-9440, pages 1967 - 1976
by applicantKR20030013795
 KR100375890B
 KR20010006460
    - GORDON ET AL., BIOCHEM BIOPHYS RES COMMUN, (1985), vol. 126, page 419
    - Remington's Pharmaceutical Science, MACK PUBLISHING COMPANY
    - YLA-HERTTUALA S; ALITALO K., NAT MED., (2003), vol. 9, no. 6, pages 694 - 701
    - KHAN TA ET AL., GENE THER, (2003), vol. 10, no. 4, pages 285 - 91
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.